Emirates

Comarch Receives "Partnership Award" from Emirates National Oil Company (ENOC)

Retrieved on: 
Monday, December 19, 2022
Mobile, Comarch, Global Smoke-Free Partnership Award, Emirates National Oil Company, Data center, Marketing, Social, Economic development, Heathrow Airport, True Value, Emirates, BP, Vietnam Airlines, ENOC, ROI, LATAM Airlines Group, Workforce, Growth, History, JetBlue, Senior, Partnership, Airline

KRAKÓW, Poland, Dec. 19, 2022 /PRNewswire/ -- A global provider of technologically advanced IT systems and services, has received a "Partnership Award" from Emirates National Oil Company (ENOC), a leading energy group that operates in the oil & gas industry.

Key Points: 
  • KRAKÓW, Poland, Dec. 19, 2022 /PRNewswire/ -- A global provider of technologically advanced IT systems and services, has received a "Partnership Award" from Emirates National Oil Company (ENOC), a leading energy group that operates in the oil & gas industry.
  • What is important, ENOC was the first company working with Comarch that decided to create a fully digital loyalty program driven by a mobile application – without any physical cards.
  • "Comarch Loyalty Management, the tool we are currently using, provides us with what is most important, and that is – short time-to-market.
  • Emirates National Oil Company Group (ENOC) is a leading integrated global oil and gas player operating across the energy sector value chain.

EQS-News: Mainz Biomed Announces IRB Approval and Initiation of US Pivotal FDA Clinical Study

Retrieved on: 
Sunday, December 18, 2022
Institutional review board, IRB, Integral, Colorectal cancer, American Cancer Society, CRC, Food, FDA, US Foods, Colon, AA, DNA, Korea Disease Control and Prevention Agency, Cancer, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NPV, Gene expression, Trial of the century, CDC, Emirates, PPV, PCR, RNA transfection, Ageing, Biomarker, United Arab Emirates, Patient, Pharmaceutical industry, Medical imaging

Mainz Biomed will now initiate the study, which will form the basis of the data package to be submitted for review by the U.S. Food and Drug Administration (FDA) to achieve marketing authorization.

Key Points: 
  • Mainz Biomed will now initiate the study, which will form the basis of the data package to be submitted for review by the U.S. Food and Drug Administration (FDA) to achieve marketing authorization.
  • ReconAAsense is a prospective clinical study that will include approximately 15,000 subjects from 150 sites across the United States.
  • Based on the study’s outcome, Mainz Biomed will decide on the integration of the biomarkers evaluated in ColoFuture’s eAArly DETECT into the ReconAAsense study.
  • ColoAlert is currently marketed across Europe and the United Arab Emirates with the intention of beginning its pivotal FDA clinical study in 2022 for US regulatory approval.

St Kitts and Nevis Prime Minister takes lessons from Dubai to position twin-island federation as a business hub

Retrieved on: 
Monday, December 12, 2022
School, Airport, Air transport agreement, Weather, Health, Travel, Government, Climate change, Hospital, GPD, CBI, Emirates, Knowledge, Education, Rainforest, Element, Federation, Miss St. Kitts & Nevis, United Arab Emirates, High commissioner, Cabinet, COVID-19, Gross domestic product, Agriculture, Airline, Medicine, Tourism, Renewable energy, Pharmaceutical industry, Basseterre

The seminal move paved the way for air traffic between the Federation of St Kitts and Nevis and the UAE.

Key Points: 
  • The seminal move paved the way for air traffic between the Federation of St Kitts and Nevis and the UAE.
  • As climate related weather patterns become more fierce, St Kitts and Nevis is looking to tap into Dubai’s knowledge and expertise in constructing durable and resilient structures.
  • St Kitts and Nevis developed and instituted its citizenship by investment programme in 1984 as a way to increase and diversify revenue generation.
  • The visit also signifies to the world St Kitts and Nevis is open for business.

Biomerica Receives KFDA and Ministry of Health Approval for Colorectal Screening and Breast Screening Tests in Saudi Arabia and UAE

Retrieved on: 
Thursday, December 8, 2022
Breast cancer, Woman, Colorectal cancer, Physician, Breast, Incidence, Ministry, Prevalence, Food, FDA, Colon, Sale, Cancer, Female, Emirates, Environment, EZ, Archive, Kingdom, Ministry of Health (Saudi Arabia), Biomedical technology, KFDA, Research, Patent, Government agency, United Arab Emirates, Public health, Medical imaging, Health

It’s the only test with no stool handling and suitable for national screening campaigns due to its convenience and cost-effectiveness.

Key Points: 
  • It’s the only test with no stool handling and suitable for national screening campaigns due to its convenience and cost-effectiveness.
  • The Aware® Breast Self Exam is a revolutionary way for women to enhance the tactile sensitivity to feel abnormalities in breast tissue.
  • About 80% of breast cancer cases are detected because women themselves notice changes in their breast (Cancer 2014; 120:20-5).
  • The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs.

Mainz Biomed Announces IRB Approval and Initiation of US Pivotal FDA Clinical Study

Retrieved on: 
Tuesday, December 6, 2022
Institutional review board, IRB, Integral, Colorectal cancer, American Cancer Society, CRC, Food, FDA, US Foods, Colon, AA, DNA, Korea Disease Control and Prevention Agency, Cancer, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NPV, Gene expression, Trial of the century, CDC, Emirates, PPV, PCR, RNA transfection, Ageing, Biomarker, United Arab Emirates, Patient, Pharmaceutical industry, Medical imaging

Mainz Biomed will now initiate the study, which will form the basis of the data package to be submitted for review by the U.S. Food and Drug Administration (FDA) to achieve marketing authorization.

Key Points: 
  • Mainz Biomed will now initiate the study, which will form the basis of the data package to be submitted for review by the U.S. Food and Drug Administration (FDA) to achieve marketing authorization.
  • ReconAAsense is a prospective clinical study that will include approximately 15,000 subjects from 150 sites across the United States.
  • Based on the study’s outcome, Mainz Biomed will decide on the integration of the biomarkers evaluated in ColoFuture’s eAArly DETECT into the ReconAAsense study.
  • ColoAlert is currently marketed across Europe and the United Arab Emirates with the intention of beginning its pivotal FDA clinical study in 2022 for US regulatory approval.

Virtusa Sponsors FutureHack 2022 by Emirates NBD with AWS

Retrieved on: 
Tuesday, December 13, 2022
HackMaster, Positive Hack Days, Culture, Oculus (brand), Fintech Valley Vizag, Pocs, Travel, POC, Global Media & Entertainment, SME, Publicis Healthcare Communications Group, Rationalization, Mentorship, Global 2000, Financial services, Emirates, Emirates NBD, OIP, Engineering, AWS, Communication, Amazon Web Services, Information technology, Online shopping, Cryptocurrency, Toy, Financial technology, Insurance, Virtusa, Partnership

FutureHack 2022 was powered by Virtusa's Open Innovation Platform (OIP) hosted on the recently launched AWS Middle East (UAE) Region.

Key Points: 
  • FutureHack 2022 was powered by Virtusa's Open Innovation Platform (OIP) hosted on the recently launched AWS Middle East (UAE) Region.
  • The challenge statements provided by Emirates NBD were focused on Seamless Smart Payments, SME Simplified, and Monetizing Your Data.
  • The shortlisted teams presented a demo of their pitches to the judging panel from Emirates NBD, HackMasters, and Virtusa.
  • Hemant Julka, SVP Head of Fintech and Partnerships, Emirates NBD, added,"It was a great experience to work closely with Virtusa, AWS, and HackMasters, to make FutureHack 2022 a success, with participation from hackers across the globe.

Dalma Capital Group Acquires The Global CIO Office: Creates Full Service Integrated Platform for Funds, Investment Banking and Wealth Advisory

Retrieved on: 
Tuesday, December 13, 2022
Merrill (company), Wall Street, CIO, JPMorgan Chase, CIOS, Barclays, Prudential, National bank, NBAD, Outsourcing, Investment, Emirates NBD, Dubai Financial Services Authority, Dubai International Financial Centre, Dubai International Airport, Acquisition, Financial services, Film, Emirates

DUBAI, UAE, Dec. 13, 2022 /PRNewswire/ -- Dalma Capital Group, a global alternative investment management platform and advisor, has agreed to acquire The Global CIO Office, an independent, outsourced chief investment officer services business with a global network of investment professionals. The Global CIO Office will become the Dalma Global CIO Office, providing outsourced chief investment officer services to family offices seeking global strategic investment advisory services with true independence. 

Key Points: 
  • The Global CIO Office will become the Dalma Global CIO Office, providing outsourced chief investment officer services to family offices seeking global strategic investment advisory services with true independence.
  • Gary Dugan, Founder and Chief Executive Officer of The Global CIO Office will be joining the Dalma Capital Group in the newly established role of Chief Investment Officer of Dalma Capital and will be responsible for managing the Dalma Global CIO Office.
  • The acquisition of The Global CIO Office completes Dalma Capital's service offering and will create a full-service integrated platform for funds, investment banking and wealth advisory.
  • Dalma Capital Group is a group of companies that includes Dalma Capital Management Limited ("Dalma Capital") - a global alternative investment management platform and advisor with strong capabilities in fund and asset management, investment banking and, following this announcement, outsourced Chief Investment Officer solutions for professional clients.

Dalma Capital Group Acquires The Global CIO Office: Creates Full Service Integrated Platform for Funds, Investment Banking and Wealth Advisory

Retrieved on: 
Tuesday, December 13, 2022
Merrill (company), Wall Street, CIO, JPMorgan Chase, CIOS, Barclays, Prudential, National bank, NBAD, Outsourcing, Investment, Emirates NBD, Dubai Financial Services Authority, Dubai International Financial Centre, Dubai International Airport, Acquisition, Financial services, Film, Emirates

DUBAI, UAE, Dec. 13, 2022 /PRNewswire/ -- Dalma Capital Group, a global alternative investment management platform and advisor, has agreed to acquire The Global CIO Office, an independent, outsourced chief investment officer services business with a global network of investment professionals. The Global CIO Office will become the Dalma Global CIO Office, providing outsourced chief investment officer services to family offices seeking global strategic investment advisory services with true independence. 

Key Points: 
  • The Global CIO Office will become the Dalma Global CIO Office, providing outsourced chief investment officer services to family offices seeking global strategic investment advisory services with true independence.
  • Gary Dugan, Founder and Chief Executive Officer of The Global CIO Office will be joining the Dalma Capital Group in the newly established role of Chief Investment Officer of Dalma Capital and will be responsible for managing the Dalma Global CIO Office.
  • The acquisition of The Global CIO Office completes Dalma Capital's service offering and will create a full-service integrated platform for funds, investment banking and wealth advisory.
  • Dalma Capital Group is a group of companies that includes Dalma Capital Management Limited ("Dalma Capital") - a global alternative investment management platform and advisor with strong capabilities in fund and asset management, investment banking and, following this announcement, outsourced Chief Investment Officer solutions for professional clients.

EQS-News: Mainz Biomed Appoints Amy Levin as Vice President of Regulatory Affairs to Oversee Global Regulatory Strategies

Retrieved on: 
Tuesday, November 29, 2022
IVD, RAC, Colonoscopy, Roche Diagnostics, Union, United Arab Emirates, Food, DNA, Knowledge, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Neoplasm, Biomarker, Regulatory affairs, Emirates, PCR, Colorectal cancer, Cancer, FIT, Health, Roche, RMD, Clinical trial, Trial of the century, CRC, FDA, Pharmaceutical industry, Vaccine, San Francisco Bay, EU

Former Roche executive Amy Levin, RAC, brings more than 20 years of regulatory affairs experience as an in vitro diagnostics (IVD) industry leader

Key Points: 
  • Former Roche executive Amy Levin, RAC, brings more than 20 years of regulatory affairs experience as an in vitro diagnostics (IVD) industry leader
    BERKELEY, US MAINZ, Germany November 29, 2022 Mainz Biomed NV (NASDAQ:MYNZ) (Mainz Biomed or the Company), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the appointment of Amy Levin, RAC, as Vice President of Regulatory Affairs.
  • In this role, Ms. Levin will be in charge of guiding the implementation and regulatory, clinical trial and quality initiatives that are related to in vitro diagnostics.
  • She will contribute to key milestones for the FDA submission process for ColoAlert, the Companys highly efficacious and easy-to-use DNA-based detection test for colorectal cancer (CRC).
  • Previously, she worked as Director, Roche Molecular Diagnostics (RMD) International Regulatory Affairs at RMD after serving in many roles with increasing leadership responsibilities within the company.

Mainz Biomed Appoints Amy Levin as Vice President of Regulatory Affairs to Oversee Global Regulatory Strategies

Retrieved on: 
Tuesday, November 29, 2022
RAC, Colonoscopy, Roche Diagnostics, Union, United Arab Emirates, Food, DNA, Knowledge, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Neoplasm, Biomarker, Regulatory affairs, Emirates, PCR, Colorectal cancer, Cancer, FIT, Health, RMD, Clinical trial, Trial of the century, CRC, FDA, Pharmaceutical industry, Vaccine, San Francisco Bay, EU

BERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (Mainz Biomed or the Company), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the appointment of Amy Levin, RAC, as Vice President of Regulatory Affairs.

Key Points: 
  • BERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (Mainz Biomed or the Company), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the appointment of Amy Levin, RAC, as Vice President of Regulatory Affairs.
  • In this role, Ms. Levin will be in charge of guiding the implementation and regulatory, clinical trial and quality initiatives that are related to in vitro diagnostics.
  • Previously, she worked as Director, Roche Molecular Diagnostics (RMD) International Regulatory Affairs at RMD after serving in many roles with increasing leadership responsibilities within the company.
  • She has also held other regulatory positions at multiple Biotechnology companies in the San Francisco Bay area.